May 14th 2025
Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.
Watch the series now!
Peter Bach, MD, MAPP, Talks About Improving Quality in Cancer Care
Michael Chernew, PhD, Discusses Challenges in Oncology Management